ArticleAlimentary pharmacology & therapeutics2022

Real-world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases.

Adriaan Volkers et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.